News
03.31.17
Genoptix Selects Zer0 to 5ive for Acquisition Announcement
Genoptix, one of the largest hematopathology centers in the United States, chose Zer0 to 5ive to announce its acquisition by leading investors, Ampersand Capital Partners and 1315 Capital. As part of the engagement, Zer0 to 5ive raised awareness of the acquisition through targeted coverage in trade, local and M&A publications.